Effets indésirables des traitements contre l’ostéoporose : comment les expliquer aux patient-e-s ? [Side effects of osteoporosis treatments: how to explain them to patients?]

Détails

Ressource 1Demande d'une copie Sous embargo jusqu'au 19/10/2024.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_0510C417447B
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Effets indésirables des traitements contre l’ostéoporose : comment les expliquer aux patient-e-s ? [Side effects of osteoporosis treatments: how to explain them to patients?]
Périodique
Revue medicale suisse
Auteur⸱e⸱s
Curraj E., Gonzalez Rodriguez E.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
19/04/2023
Peer-reviewed
Oui
Volume
19
Numéro
823
Pages
746-751
Langue
français
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Résumé
Despite the effectiveness of osteoporosis treatments, fear of side effects reduces both their prescription by doctors, and their acceptance by patients. The most common side effects are benign and transient, such as flu-like symptoms after zoledronate infusion, or nausea and dizziness after teriparatide introduction. On the other hand, the dreaded osteonecrosis of the jaw is very rare and associated with known risk factors. Only vertebral fractures after stopping denosumab make this treatment a matter for experienced practitioners. Therefore, knowing the side effects of prescribed treatments and explaining them to patients is essential to promote adherence.
Mots-clé
Humans, Female, Bone Density Conservation Agents/adverse effects, Denosumab/adverse effects, Osteoporosis/chemically induced, Osteoporosis/drug therapy, Teriparatide/adverse effects, Zoledronic Acid/therapeutic use, Drug-Related Side Effects and Adverse Reactions, Osteoporosis, Postmenopausal/drug therapy, Osteoporotic Fractures, Diphosphonates/adverse effects
Pubmed
Création de la notice
08/05/2023 13:49
Dernière modification de la notice
18/11/2023 8:08
Données d'usage